Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
Overview | Financials
Company Name | Phathom Pharmaceuticals, Inc. |
Symbol | PHAT |
Currency | USD |
Price | 18.37 |
Market Cap | 1,254,479,952 |
Dividend Yield | 0% |
52-week-range | 6.065 - 19.71 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Ms. Terrie J. Curran |
Website | https://www.phathompharma.com |
An error occurred while fetching data.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD